ESMO 23: Non-Squamous NSCLC Population Props Up Dato-DXd In TROPION-Lung01

Data from a histological subgroup have come to the rescue for AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd along with reassurance over its safety profile in advanced NSCLC, while overall survival data are still awaited.